ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis

Ying Guo; Yuan Zhou; Shohei Yamatomo; Hui Yang; Peng Zhang; Shi Chen; Stephen D Nimer; Zhizhuang Joe Zhao; Mingjiang Xu; Jie Bai; Feng-Chun Yang

doi:10.1038/s41375-018-0347-y

ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis

Leukemia. 2019 May;33(5):1287-1291. doi: 10.1038/s41375-018-0347-y. Epub 2019 Jan 16.

Authors

Ying Guo^#^{1

2}, Yuan Zhou^#³, Shohei Yamatomo^{1

2}, Hui Yang^{1

2}, Peng Zhang^{1

2}, Shi Chen^{1

2}, Stephen D Nimer^{1

2}, Zhizhuang Joe Zhao⁴, Mingjiang Xu^{1

2}, Jie Bai^{5

6}, Feng-Chun Yang^{7

8}

Affiliations

¹ Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
² Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA.
³ State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
⁴ Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
⁵ State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. janebai86@hotmail.com.
⁶ Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin, China. janebai86@hotmail.com.
⁷ Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. fxy37@med.miami.edu.
⁸ Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA. fxy37@med.miami.edu.

^# Contributed equally.

PMID: 30651633
DOI: 10.1038/s41375-018-0347-y

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Amino Acid Substitution
Disease Progression
Epistasis, Genetic*
Gene Expression Regulation*
Genetic Predisposition to Disease*
Humans
Janus Kinase 2 / genetics*
Mutation*
Primary Myelofibrosis / genetics*
Primary Myelofibrosis / metabolism
Primary Myelofibrosis / mortality
Primary Myelofibrosis / pathology
Prognosis
Repressor Proteins / genetics*

Substances

ASXL1 protein, human
Repressor Proteins
JAK2 protein, human
Janus Kinase 2

Grants and funding

R01 CA172408/CA/NCI NIH HHS/United States